Biotech
News Alert: GenSpera (OTCQB:GNSZ) Presents at BIO CEO & Investor Conference
Company Plans
for Multi-Pronged, Long Term Expansion of Novel Treatment Platform
NEW
YORK - February 2, 2015 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ)
announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera,
will present at the 17th Annual BIO CEO & Investor Conference on February
9th at 1 p.m. at the Waldorf Astoria in New York City. The presentation comes
as GenSpera continues clinical development of mipsagargin for several tumor
types and expands the applicability of its innovative mechanism of action in a
broad array of oncology treatments.
The presentation will provide an update on
GenSpera's long-term business growth plans, recent clinical achievements for
mipsagargin in the treatment of hepatocellular carcinoma (HCC), and its ongoing
Phase II trials in glioblastoma and prostate cancer. Last month, GenSpera
presented positive Phase II study results for mipsagargin in treating HCC at
the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif.,
demonstrating a proof of concept for its intellectual property. A live webcast
of the BIO CEO presentation will be broadcast at: http://www.veracast.com/webcasts/bio/ceoinvestor2015/37117595001.cfm.
"We have reached an important
milestone with positive Phase II results, which demonstrated that mipsagargin
works as designed and destroys established tumor vasculature while sparing
patients the debilitating side effects of traditional chemotherapy," said
Dionne. "We are confident that this now proven state-of-the-art precision
approach has every potential to be a game changer in how we treat cancer."
Mipsagargin's mechanism of action works by
targeting the enzyme prostate-specific membrane antigen (PSMA), which is highly
expressed in all cancer tumor vasculature and in prostate cancer cells. The
Phase II study results presented in San Francisco demonstrated that the prodrug
effectively stabilizes progression of HCC by reducing blood flow within tumors
while not affecting blood flow within normal tissues. The study also showed
indications that patients had improved quality of life and fewer side effects
than typically seen in cancer treatment. After successfully demonstrating its
proof of concept, GenSpera will move forward with plans to show that
mipsagargin is effective across a broad array of tumor indications.
"We are committed to the ongoing
development of our technology and working to change the landscape of oncology
treatment," continued Dionne. "We believe that the positive clinical
results we have observed with mipsagargin will extend to other drug candidates
in our portfolio."
Identifying ground-breaking oncology
treatments that circumvent side effects, particularly in hard to treat cancers
is a key area of oncology research. In the United States, more than 33,000 new
cases of HCC will be diagnosed in 2015. Globally, liver cancer is a primary
public health issue with more than 700,000 people diagnosed and more than
600,000 deaths annually. There is currently only one approved treatment
available for liver cancer.
Additionally,
more than 13,000 new cases of glioblastoma are diagnosed in the U.S. each year.
The 17th Annual BIO CEO & Investor
Conference is the largest independent investor conference focused on
publicly-traded biotechnology companies. The conference is designed to foster
an informative dialogue between institutional investors and senior
biotechnology executives about emerging and current investment opportunities.
The 2014 BIO CEO & Investor Conference featured 1,820 partnering meetings,
149 company presentations and 1,400 attendees, over half of which were
investors.
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2015/02021.asp
About GenSpera
GenSpera Inc. is a San Antonio-based
biotech company that unlocks conventional thinking to conceive, design, and
develop cancer therapies. GenSpera's technology platform combines a powerful,
plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system
that provides for the targeted release of drug candidates within tumors.
GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug
designation by the US Food and Drug Administration (FDA) in 2013 for evaluation
in patients with hepatocellular carcinoma (liver cancer).
For additional information on GenSpera,
visit www.genspera.com and connect on
Twitter @GenSperaNews,LinkedIn, Facebook, YouTube and Google+.
Cautionary
Statement Regarding Forward Looking Information
This communication may contain
forward-looking statements. Investors are cautioned that statements in this
document regarding potential applications of GenSpera's technologies or the
future prospects of the company constitute forward-looking statements that
involve risks and uncertainties, including, without limitation, risks inherent
in the development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for future
capital, dependence upon collaborators and maintenance of our intellectual
property rights and the acceptance of GenSpera's proposed therapies by the
health community. Actual results may differ materially from the results
anticipated in these forward-looking statements. Additional information on
potential factors that could affect our results and other risks and uncertainties
will be detailed from time to time in GenSpera's periodic reports filed with
the Securities and Exchange Commission.
Disclaimer/Disclosure:
The Investorideas.com newswire is a third party publisher of news and research
as well as creates original content as a news source. Original content created
by investorideas is protected by copyright laws other than syndication rights.
Investorideas is a news source on Google news and Linkedintoday plus hundreds
of syndication partners. Our site does not make recommendations for purchases
or sale of stocks or products. Nothing on our sites should be construed as an
offer or solicitation to buy or sell products or securities. All investment
involves risk and possible loss of investment. This site is currently
compensated by featured companies, news submissions, content marketing and
online advertising. Contact each company directly for press release questions.
Disclosure is posted on each release if required but otherwise the news was not
compensated for and is published for the sole interest of our readers.
Disclosure: GNSZ is a previous showcase company which expired on December 18,
2014. Investorideas is long 144 shares
BC Residents and Investor Disclaimer:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
